The Childhood Cancer Blog

The Childhood Cancer Blog

Welcome to The Childhood Cancer Blog
from Alex's Lemonade Stand Foundation!

Open to all institutions in the U.S. and Canada,  Alex’s Lemonade Stand Foundation’s Travel for Care program offers assistance to families who face the need to travel for potentially lifesaving childhood cancer treatment. Assistance for transportation and lodging may be available to families who meet program guidelines and apply through a member of their medical team.

After three years of treatment for neuroblastoma, Elijah Talley had exhausted options at his hometown hospital in Little Rock, Arkansas. Diagnosed when he was just 4 years old, Elijah went through the endless cycle of treatment and relapse, again and again. Conventional treatments, which included high dose chemotherapy, radiation and a stem cell transplant, failed.

Neuroblastoma, the most common type of extra-cranial solid tumor in children, can range from benign to... Read More

Little Sophia, who is now 8-years-old and a survivor of Wilms’ tumor, the most common type of kidney cancer in children, describes herself  as “one tough cookie.”

“I want chocolate milk, IMMEDIATELY,” those were 4-year-old Sophia’s first words following a seven-hour surgery to remove a tumor on her kidney. 

It is no surprise that little Sophia, who is now 8 years old and a survivor of Wilms’ tumor, the most common type of kidney cancer in children, describes herself  as “one tough cookie.”

Wilms’ tumor typically presents itself as a painless swelling of the belly. In Sophia’s case, her pediatrician noticed it at her routine 4-year-old checkup. For other... Read More

In August 2017, the FDA approved CAR (Chimeric Antigen Receptor) T Cell immunotherapy as a treatment for certain types of ALL. This is the first gene therapy to achieve FDA approval in the United States and one of the few major breakthroughs and approvals for pediatric oncology in recent years.

Relapsed Pre-B cell acute lymphoblastic leukemia (ALL) has a notoriously low remission rate—but now, thanks to childhood cancer researchers and the FDA, there is more hope on the horizon. 

In August 2017, the FDA approved CAR (Chimeric Antigen Receptor) T Cell immunotherapy as a treatment for certain types of ALL. This is the first gene therapy to achieve FDA approval in the United States and one of the few major breakthroughs and approvals for pediatric oncology in recent years. 

Like other... Read More

Pages